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Conclusions: New American College of Cardiology-American Heart
Association (ACC-AHA) guidelines for the management of cholesterol
could increase the number of adults who would be eligible for statin therapy
by 12.8 million. Most of the increase will be seen among older adults
without known cardiovascular disease.
Summary: The ACC-AHA new guidelines for management of
cholesterol were released in November of 2013. The new guidelines recom-
mended treatment of patients with LDL cholesterol of 70 mg per deciliter if
they have either diabetes or a ten-year risk of cardiovascular disease of 7.5%
or more. In addition, the new guidelines expanded the treatment recom-
mendations for statin therapy to all patients with known cardiovascular dis-
ease regardless of the LDL cholesterol level. The authors utilized National
Health and Nutrition Examination Surveys (NHANES) to estimate the
number of persons in the United States for whom statin therapy would
be recommended on the basis of the new guidelines as compared with
the previous guidelines. NHANES data from 2005 to 2010 was used.
Data provided a risk-factor proﬁle of persons for whom statin therapy would
be recommended under the new ACC-AHA guidelines as compared with
the Third Adult Treatment panel (ATP-III) of the National Cholesterol Ed-
ucation Program. Data was then extrapolated to a population of 115.4
million U.S. adults between the ages of 40 and 75 years. Compared with
ATP-III guidelines, the new guidelines would increase the number of
U.S. adults receiving or eligible for statin therapy from 43.2 million
(37.5%) to 56.0 million (48.6%). 10.4 million of this 12.8 million increase
would occur among adults without cardiovascular disease. Among adults
between the ages of 60 and 75 years without cardiovascular disease not
receiving statin therapy, the percentage that would be eligible for such ther-
apy would increase from 30.4% to 87.4% among men and from 21.2% to
53.6% among women. This effect is driven largely by the increased number
of adults who would be classiﬁed solely on the basis of their estimated ten-
year risk of a cardiovascular event. Those eligible for statin therapy would
include more men than women and persons with a higher blood pressure
but a markedly lower level of LDL cholesterol.
Comment: As compared with the ATP-III guidelines, new guidelines
would recommend statin therapy for more adults who would be expected to
have future cardiovascular events (higher sensitivity) and would also include
many adults who would not have future events (lower speciﬁcity). It is
important to keep in mind that the new guidelines also call for an informed
risk-beneﬁt discussion between the patient and physician before initiation of
statin therapy. Thus, even though the risk of statins are quite low, it is
possible a number of patients would opt-out of taking a pill for which
they don’t have a speciﬁc indication or be dissuaded by the infrequent
but well-reported complications of statin therapies such as myositis, poten-
tial cataract formation, etc. Thus, based on individual patient discussions,
the number of patients actually receiving statin therapy in accordance to
the new guidelines may be less than estimated here.Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and
Aortic Arch Plaques
Amarenco P, Davis S, Jones EF, et al; and the Aortic Arch Related Cerebral
Hazard Trial Investigators. Stroke 2014;45:1248-57.
Conclusions: A combination of the primary end point of cerebral
infarction, myocardial infarction, peripheral embolism, vascular death, or
intracranial hemorrhage in patients with aortic plaque is no different in those
treated with a combination of clopidogrel and aspirin vs those treated with
warfarin.
Summary: It is known that atherosclerosis of the aortic arch can pro-
duce cerebral embolism, particularly when the plaque is$4 mm in thickness
(Jones EF et al, Stroke 1995; 26:218-24). In patients with prior ischemic
stroke, risk of recurrent stroke or other vascular events in those with aortic
plaque $4 mm in thickness is three to four times higher than in individuals
with plaques <4 mm or no plaque of the aortic arch (Tunick PA et al, J Am
Coll Cardiol 1994;23:1085-90). Optimal treatment of patients with aortic
plaques is unknown. The authors hypothesized that a combination of aspirin
plus clopidogrel would be 25% superior to dose-adjusted warfarin for pre-
vention of new vascular events in patients with aortic plaques. They per-
formed a multicenter prospective, randomized, controlled trial, with
blinded end point evaluation of aspirin 75 mg/d plus clopidogrel 75 mg/
d vs warfarin (international normalized ratio, 2-3) in patients with ischemic
stroke, transient ischemic attack or peripheral embolism associated with
thoracic aortic plaque $4 mm and no other identiﬁed source of embolism
while on best medical therapy. This was an investigator-driven trial funded
by the French government and the Australian National Health and Medical
Research Council. The primary end point included cerebral infarction,
myocardial infarction, peripheral embolism, vascular death, or intracranial
hemorrhage. Follow-up visits occurred at 1 month and every 4 months
following randomization. After 349 patients were entered, the trial was
stopped with randomization having occurred over a period of 8 years and
3 months. After median follow-up of 3.4 years, the primary end occurred
in 7.6% (13/172) and 11.3% (20/177) of patients on aspirin and clopidog-
rel (A+C) and warfarin, respectively (log-rank, P ¼ .2). The adjusted hazard
ratio was 0.76 (95% CI, 0.36-1.61; P ¼ .5). Major hemorrhages, including
intracranial hemorrhage, occurred in 4 and 6 patients in the A+C and
warfarin groups, respectively. Vascular deaths occurred in 0 patients in
the A+C group compared with 6 (3.4%) patients in the warfarin arm
(log-rank, P ¼ .013). Time in therapeutic range (67% of the time for in-
ternational normalized ratio 2-3) analysis by tertiles showed no signiﬁcant
differences across groups.
Comment: The study highlights the aortic arch as a source of stroke
and peripheral embolism. The study certainly has implications for those
manipulating wires within the aortic arch as part of an endovascular proce-
dure and for those treating people with occult peripheral embolism and a
suspected thoracic aortic source. While relatively underpowered, the study
provides the best information to date on the treatment of patients with
aortic plaques and a suspected thoracic aortic source for cerebral or distal
embolism. It is unlikely more deﬁnitive date is going to be available anytime
soon.
